Results 41 to 50 of about 164 (107)

Real-World Treatment Outcomes in Black, Hispanic, Asian, and White People with Multiple Sclerosis Treated with Fumarates in the USA

Neurology and Therapy
Introduction Multiple sclerosis (MS) is a heterogeneous disease affecting a diverse population. Compared with white people with MS (PwMS), Black PwMS have more severe disease and higher incidence of MS, whereas Hispanic PwMS experience earlier onset ...
Sophia Woodson, Edward J. Gettings, Chu-Yueh Guo, Sylvia Klineova, Jong-Mi Lee, Rebecca S. Romero, Aljoeson Walker, Kinyee Fong, Jason P. Mendoza, Nicholas Belviso, Boyang Bian, James B. Lewin, Sai L. Shankar   +12 more
doaj   +1 more source

Fumarate-based drugs protect against neuroinflammation via upregulation of anti-ferroptotic pathways

Journal of Neuroinflammation
Ferroptosis is defined as iron dependent non-apoptotic cell death. It is based on peroxidation of polyunsaturated phospholipids and subsequent membrane rupture.
Katinka Fischer, Leonie Thewes, Tim Prozorovski, Mary Bayer, Michael Dietrich, Torsten Lowin, Philipp Albrecht, Hans-Peter Hartung, Sven G. Meuth, Orhan Aktas, Carsten Berndt   +10 more
doaj   +1 more source

Generics, Biosimilars and Follow‐On Non‐Biologic Complex Drugs for Multiple Sclerosis: A Narrative Review of the Regulatory and Clinical Implications for European Neurologists

European Journal of Neurology, Volume 32, Issue 4, April 2025.
ABSTRACT Background Multiple sclerosis (MS) places substantial socioeconomic burden on patients due to its early onset and progressive nature, but healthcare systems are also impacted by the high costs of disease‐modifying treatments (DMTs). The use of generics (for conventional drugs), biosimilars (for biologics) or follow‐on versions of non‐biologic ...
Thomas Berger, Markus Zeitlinger, Veronica Popescu, Melinda Magyari, Laura Airas, Mona Alkhawajah, Maura Pugliatti, Magd Zakaria, Carlo Pozzilli, Jelena Drulovic, Bart Van Wijmeersch, Patrick Vermersch, Celia Oreja‐Guevara   +12 more
wiley   +1 more source

Inflammatory disease in people with multiple sclerosis treated with immune checkpoint inhibitors

Annals of Clinical and Translational Neurology, Volume 12, Issue 3, Page 643-647, March 2025.
Abstract This study evaluated disease activity in people with Multiple Sclerosis (PwMS) who received immune checkpoint inhibitors (ICIs) compared to PwMS not treated with ICIs. There were 108 PwMS included (27 PwMS+ICIs and 81 PwMS controls), matched on age, sex, disease duration, DMTs, and MS disease course. Of 27 PwMS+ICIs, one (4%) had a relapse and
Saira Afzal, Yadi Li, Brittany Lapin, Le H. Hua, Lucy Boyce Kennedy, Wen Wee Ma, Marisa McGinley, Jeffrey A. Cohen, Amy Kunchok   +8 more
wiley   +1 more source

Immunomodulators and immunosuppressants for progressive multiple sclerosis: A network meta-analysis (Protocol) [PDF]

, 2022
Background: Recent years have seen a broader range of immunomodulatory and immunosuppressive treatment options for people with progressive forms of multiple sclerosis (PMS).
Ridley, Ben, Piggott, Thomas, Filippini, Graziella, Baldin, Elisa, Nonino, Francesco, Gonzalez-Lorenzo, Marien, Del Giovane, Cinzia, Foschi, Matteo, Tramacere, Irene, Minozzi, Silvia, Peryer, Guy   +10 more
core   +1 more source

Ethnoracial disparities in gray matter atrophy are mediated by structural disconnectivity in multiple sclerosis

Annals of Clinical and Translational Neurology, Volume 12, Issue 3, Page 615-630, March 2025.
This study aimed to assess gray matter (GM) atrophy, the contribution of white matter (WM) lesions, and consequent structural disconnectivity in minority patients with multiple sclerosis (PwMS). Minority PwMS were found to have greater lesion burden and GM atrophy. Differences in GM atrophy were partially mediated by WM pathology. Abstract Objective To
Ahmed Bayoumi, Joseph A. Thomas, Breanna R. Alonzo, Juan Jimenez, Christopher M. Orlando, Carlos A. Pérez, Khader M. Hasan, Jerry S. Wolinsky, John A. Lincoln   +8 more
wiley   +1 more source

Evolving Patterns of Initial RRMS Treatment in Finland (2013–2022): Insights From a Nationwide Multiple Sclerosis Register

Brain and Behavior, Volume 15, Issue 2, February 2025.
ABSTRACT Background The treatment of relapsing‐remitting multiple sclerosis (RRMS) is changing. There are limited data about initial treatment of RRMS in Finland. Objective Our objectives were to study the trends of initial disease‐modifying treatments (DMTs) for patients with RRMS from 2013 to 2022, treatment delays, factors associated with DMT choice,
Henrik Ahvenjärvi, Elina Jokinen, Matias Viitala, Henri Autio, Anne M. Portaankorva, Merja Soilu‐Hänninen, Johanna Krüger, Mervi Ryytty   +7 more
wiley   +1 more source

De‐Escalation of Disease‐Modifying Therapy in Multiple Sclerosis—A Danish Nationwide Cohort Study

European Journal of Neurology, Volume 32, Issue 2, February 2025.
ABSTRACT Background and Objective High‐efficacy (HE) disease‐modifying therapies (DMT) are increasingly used to treat multiple sclerosis (MS). Concerns arise when considering the decreasing efficacy and increasing risk of adverse events in aging patients.
Frederik Elberling, Mie Reith Mahler, Luigi Pontieri, Finn Sellebjerg, Melinda Magyari, for the DMSG Study Group   +5 more
wiley   +1 more source

Subclinical imaging activity in multiple sclerosis patients during war‐related psychological stress

Annals of Clinical and Translational Neurology, Volume 12, Issue 1, Page 17-25, January 2025.
Abstract Objectives Psychological stress has been suggested as a contributory factor in the onset and progression of multiple sclerosis (MS). The 7 October 2023 terrorist attacks in Israel caused significant psychological stress, providing a unique context to study its impact on MS activity.
Omri Zveik, Tal Friedman‐Korn, Ariel Rechtman, Tal Ganz, Garrick Hoichman, Lyne Shweiki, Dana Ekstein, Adi Vaknin‐Dembinsky   +7 more
wiley   +1 more source

Effect of Different Treatments on Retinal Thickness Changes in Patients With Multiple Sclerosis: A Review

CNS Neuroscience &Therapeutics, Volume 31, Issue 1, January 2025.
ABSTRACT Background Multiple sclerosis (MS) is an autoimmune disorder affecting the central nervous system, with varying clinical manifestations such as optic neuritis, sensory disturbances, and brainstem syndromes. Disease progression is monitored through methods like MRI scans, disability scales, and optical coherence tomography (OCT), which can ...
Armin Adibi, Iman Adibi, Milad Javidan
wiley   +1 more source